Fate Therapeutics to present new off-the-shelf CAR T-cell therapies for cancer and autoimmune diseases at ASGCT 2026.

Fate Therapeutics announced it will showcase data on its off-the-shelf CAR T-cell therapies FT819, FT839, and FT836 at the 2026 ASGCT Annual Meeting. These therapies target cancer and autoimmune diseases like systemic lupus erythematosus, rheumatoid arthritis, and type 1 diabetes, offering novel treatment options without the need for conditioning chemotherapy. The presentations include clinical trial updates and preclinical data highlighting the therapies' potential to improve patient outcomes and work alongside existing treatments. This highlights Fate's progress in developing innovative cellular immunotherapies derived from induced pluripotent stem cells.